Investor Relations

Birgit Girshick became Chief Executive Officer of Charles River Laboratories in May 2026. Ms. Girshick joined Charles River in 1989 and held positions of increasing responsibility in the Company’s Research Models & Services and Avian Vaccine Services businesses. In 2004, she was promoted to General Manager of the Avian Vaccine Services business. She was named Corporate Vice President, Global Biopharmaceutical Services (now Biologics Testing Solutions), in 2010. In 2013, Ms. Girshick was promoted to Corporate Senior Vice President, Research Models and Biologics Testing Solutions. In 2016, Ms. Girshick assumed responsibility for leading the WIL integration, and in October 2016, was named head of the global Discovery Services business.

In 2018, Ms. Girshick was promoted to Corporate Executive Vice President overseeing the Discovery, Safety Assessment, Biologics Testing Solutions, and Avian Vaccine Services businesses. In 2021, she also assumed responsibility for the company’s Cell and Gene Therapy CDMO business. In October 2021, Ms. Girshick was promoted to Chief Operating Officer, and assumed the additional oversight of the Research Models and Services business, where she began her Charles River career in 1989, as well as the Microbial Solutions business. In the Chief Operating Officer role, Ms. Girshick was responsible for leading the Company’s global business units, which includes guiding their strategic direction, driving operational excellence and growth, maintaining client and partnership relationships, leading the organization’s digital transformation and integrating acquisitions.

Ms. Girshick is a member of the Board of Directors of Charles River Laboratories.

Ms. Girshick received a B.A. degree from Eastern Connecticut State University and an M.B.A. degree from the University of Rhode Island. She also received a certificate from the Advanced Management Program from Massachusetts Institute of Technology’s Sloan School of Management.